129 related articles for article (PubMed ID: 24064437)
1. Role of fidaxomicin for the treatment of Clostridium difficile infection.
Juang P; Hardesty JS
J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.
Walsh L; Lavelle A; O'Connor PM; Hill C; Ross RP
Gut Microbes; 2024; 16(1):2342583. PubMed ID: 38722061
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.
Reveles KR; Backo JL; Corvino FA; Zivkovic M; Broderick KC
Pharmacotherapy; 2017 Dec; 37(12):1489-1497. PubMed ID: 29044643
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.
Sclar DA; Robison LM; Oganov AM; Schmidt JM; Bowen KA; Castillo LV
Clin Drug Investig; 2012 Aug; 32(8):e17-24. PubMed ID: 22708825
[TBL] [Abstract][Full Text] [Related]
7. Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
Chen C; Doll NK; Casadei G; Bremner JB; Lewis K; Kelso MJ
Bioorg Med Chem Lett; 2014 Jan; 24(2):595-600. PubMed ID: 24360560
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.
Chaparro-Rojas F; Mullane KM
Infect Drug Resist; 2013; 6():41-53. PubMed ID: 23843696
[TBL] [Abstract][Full Text] [Related]
9. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis: is fidaxomicin worth the cost?
Shah H; Doyle JJ; Belletti DA
Clin Infect Dis; 2014 Feb; 58(4):603-4. PubMed ID: 24300041
[No Abstract] [Full Text] [Related]
11. Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
Jung E; Kraimps A; Dittmann S; Griesser T; Costafrolaz J; Mattenberger Y; Jurt S; Viollier PH; Sander P; Sievers S; Gademann K
Chembiochem; 2023 Dec; 24(24):e202300570. PubMed ID: 37728121
[TBL] [Abstract][Full Text] [Related]
12. Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.
Dorst A; Berg R; Gertzen CGW; Schäfle D; Zerbe K; Gwerder M; Schnell SD; Sander P; Gohlke H; Gademann K
ACS Med Chem Lett; 2020 Dec; 11(12):2414-2420. PubMed ID: 33329763
[TBL] [Abstract][Full Text] [Related]
13. Formal Single Atom Editing of the Glycosylated Natural Product Fidaxomicin Improves Acid Stability and Retains Antibiotic Activity.
Ferrara I; Chesnokov GA; Dittmann S; Blacque O; Sievers S; Gademann K
JACS Au; 2024 Jun; 4(6):2267-2280. PubMed ID: 38938792
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
Scott LJ
Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
Chahine EB; Sucher AJ; Mantei K
Consult Pharm; 2014 Sep; 29(9):614-24. PubMed ID: 25203410
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a multidrug resistant C. difficile meat isolate.
Mooyottu S; Flock G; Kollanoor-Johny A; Upadhyaya I; Jayarao B; Venkitanarayanan K
Int J Food Microbiol; 2015 Jan; 192():111-6. PubMed ID: 25440554
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
Zhanel GG; Walkty AJ; Karlowsky JA
Can J Infect Dis Med Microbiol; 2015; 26(6):305-12. PubMed ID: 26744587
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile infection: guideline-based diagnosis and treatment.
Lübbert C; John E; von Müller L
Dtsch Arztebl Int; 2014 Oct; 111(43):723-31. PubMed ID: 25404529
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
